Apollo Technology Capital Corporation, a significant shareholder of MediPharm Labs Corp., has issued voting recommendations ahead of the company's 2025 Annual and Special Meeting of Shareholders scheduled for June 16. Apollo Capital, owning approximately 3.0% of MediPharm's common stock, urges shareholders to disregard MediPharm's green proxy card and instead vote for the gold proxy card in support of Apollo Capital's six director nominees. These nominees-John Fowler, Alan D. Lewis, David Lontini, Demetrios Mallios, Regan McGee, and Scott Walters-are presented as highly qualified candidates capable of addressing issues such as strategic failures and excessive executive compensation at MediPharm. Apollo Capital has launched a campaign website, CureMediPharm.com, to outline their five-pillar plan aimed at restoring value and accountability to the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.